{"id":"W3005499534","doi":"10.1007/s10637-020-00904-7","title":"A Canadian cancer trials group phase IB study of durvalumab (anti-PD-L1) plus tremelimumab (anti-CTLA-4) given concurrently or sequentially in patients with advanced, incurable solid malignancies","year":2020,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Calgary; Ottawa Hospital; Princess Margaret Cancer Centre; BC Cancer Agency; Juravinski Cancer Centre; Queen's University","funders":"Canadian Cancer Society Research Institute","keywords":"Tremelimumab; Durvalumab; Tolerability; Medicine; Adverse effect; Internal medicine; Cohort; Oncology; Cancer; Nivolumab; Immunotherapy; Ipilimumab","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001799266,0.001921926,0.002421216,0.0005065977,0.0009865974,0.001187998,0.001298512,0.001182273,0.004592601],"category_scores_gemma":[0.0011658,0.0006166171,0.001674013,0.0009276939,0.001460147,0.0006673167,0.0003832954,0.003774142,0.0007983617],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.008282213,"about_ca_system_score_gemma":0.013236,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.1352943,"about_ca_topic_score_gemma":0.3834715,"domain_scores_codex":[0.9994395,0.0001816716,0.00001823226,0.00009069675,0.00007582059,0.0001940239],"domain_scores_gemma":[0.9990939,0.0000919601,0.00009356187,0.00004250901,0.0000611842,0.0006168133],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8702255,0.02752079,0.005107794,0.000752918,0.002167909,0.0001643837,0.0002355244,0.002204045,0.009679439,0.0004887098,0.01166475,0.06978805],"study_design_scores_gemma":[0.8421107,0.1280706,0.01881753,0.00004589789,0.001093005,0.000169939,0.0001015688,0.001072112,0.0009810488,0.0002911407,0.007196011,0.00005044822],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9739181,0.006057445,0.0004483032,0.002542846,0.0005519142,0.004228363,0.004585548,0.0001345956,0.00753282],"genre_scores_gemma":[0.9745401,0.005044845,0.002658258,0.002418356,0.0003377996,0.00233765,0.005679895,0.00004567977,0.006937315],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.8647057,"threshold_uncertainty_score":0.2690135,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05438185365786288,"score_gpt":0.3286903091132746,"score_spread":0.2743084554554117,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}